secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2026-01-29T23:59:59+00:00
Accession:  0001493152-26-004089
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics provides corporate update; debt reduced by $3.1M, IND planned for Q4 2026
--------------------------------------------------------------------------------

- Term debt and notes payable reduced to $0.7M at Dec 31, 2025, from $3.8M at Dec 31, 2024 (unaudited).
- G&A expenses cut by $2.3M in first nine months of 2025 vs same period 2024.
- Plans to file IND for CLD-401 in Q4 2026 targeting NSCLC, triple-negative breast, and head/neck cancer.
- Expects proof-of-concept data for RedTail platform in non-oncology indications and BiTE delivery with T-cell amplifiers.
- New CEO Eric Poma, PhD (appointed 2025) and CMO Guy Travis Clifton, MD bring biopharma experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226004089/0001493152-26-004089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226004089/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-004089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer